Squarepoint
NAVB

Squarepoint’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Squarepoint’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,836
Closed -$58K – 4018
2021
Q1 		$58K Buy
+28,836
New +$67.5K ﹤0.01% 2980
2016
Q3 		– Sell
-6,930
Closed -$74K – 1393
2016
Q2 		$74K Buy
+6,930
New +$136K ﹤0.01% 997

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Squarepoint's NAVB Position: Q2 2021 in Review

Squarepoint sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2021, closing a stake of 28,836 shares — an estimated $58K sold.

Squarepoint first reported a position in NAVB in Q2 2016 and held it in 2 quarters. The position peaked at $74K in Q2 2016. 31 funds tracked by Wall St. Rank hold NAVB as of Q2 2021.

  • Squarepoint reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2021 after selling out during the quarter.
  • Squarepoint sold 28,836 Navidea Biopharmaceuticals Inc. shares in Q2 2021, an estimated $58K.
  • Squarepoint first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2016 and held it in 2 quarters.
  • Squarepoint's Navidea Biopharmaceuticals Inc. position peaked at $74K in Q2 2016.
  • 31 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.